Early SGLT2i therapy in patients with T2DM and ACS results in reduction in cardiovascular and renal outcomes- a propensity score matched multi-model retrospective registry analysis

30 August 2025 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Diabetes and the heart (1) Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

ESC 365 is supported by

ESC 365 is supported by